Copenhagen researchers gave 108 adults with alcohol use disorder and obesity weekly shots or placebo alongside CBT, and blood tests backed up the drop.
Recap by typeshit. Full story at Yahoo Health.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
TradingKey sees MariTide, a GLP-1 and GIP antibody-peptide conjugate, as Amgen's biggest growth bet, with Q2 revenue at $10.1 billion and guidance raised.
Building it will employ 4,000 workers, with 600 jobs once running. Foundayo is under review in over 40 countries, with a global rollout targeted for 2027.
Loading…